Registry for hereditary autoinflammatory diseases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The AIDA registry collects data on hereditary autoinflammatory diseases and related conditions to better understand their clinical manifestations and treatment outcomes. Utilizing a secure online platform, the registry aims to identify associations between various factors such as gender and disease duration, and to compare clinical phenotypes between pediatric and adult patients. Over the next decade, the project seeks to enhance international collaboration and knowledge sharing regarding these rare diseases, ultimately improving patient care and treatment strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* to be diagnosed with a monogenic AID according to the clinical phenotype and the detection of a confirmative genotype;
* to be diagnosed with clinical familial Mediterranean fever or Behçet's disease or Still disease or PFAPA syndrome or Schnitzler's disease or CRMO according to the corresponding clinical diagnostic and/or classification criteria;
* to be diagnosed with undifferentiated systemic AID;
* to be diagnosed with non-infectious uveitis according to the standardization for uveitis nomenclature (SUN) criteria;
* to be diagnosed with anterior or posterior non-infectious scleritis;
* to be diagnosed with spondyloarthritis according to ASAS and/or New York criteria;
* to be diagnosed with Castleman disease;

Exclusion Criteria:

\- informed consent/assent not provided by the patient and/or his/her legal representative.

Where it's running

• University Algiers 1
  Algiers, Algeria Recruiting
• Université M'Hamed Bougara de Boumerdas
  Boumerdas, Algeria Recruiting
• Flinders University
  Adelaide, Australia Recruiting
• University of Adelaide
  Adelaide, Australia Recruiting
• Antwerp University Hospital
  Antwerp, Belgium Recruiting
• Hospital das Clinicas da Faculdade de Medicina HCFMUSP
  São Paulo, Brazil Recruiting

+62 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Luca Cantarini, MD,PhD
• Email: cantarini@unisi.it
• Phone: +393479385457

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ocular Fluid Work-up in Presumed Trematode-Induced Granulomatous Uveitis

  This study tests ocular fluid samples from patients with presumed trematode-induced granulomatous uveitis who are having eye surgery to look for clues about the cause.

  Recruiting Kasr El Aini Hospital · Cairo, Giza Governorate · NCT07885137

• PANDA-ASOCT: Detecting Uveitis in Children with Automated Eye Image Analysis

  This study tests a high-speed, non-invasive eye imaging system with automated analysis to help detect uveitis in children and young people who attend a clinic for uveitis or juvenile idiopathic arthritis.

  Recruiting Sheffield Children's NHS Foundation Trust · Sheffield, South Yorkshire · NCT07813598

• Arumakimig (MAS825) in VEXAS syndrome: 52 weeks to see if it helps people on steroids

  This study tests whether arumakimig can help adults with VEXAS syndrome who are taking glucocorticoids, compared with a placebo, over a year (with an option for a long-term extension).

  Recruiting at 6 sites Phase 2 Novartis · Yokohama, Kanagawa and 5 other locations · NCT07748624

• Validation of the 2025 Axial Spondyloarthritis Classification Criteria in Chinese patients

  This study tests whether the 2025 ASAS-SPARTAN criteria correctly classify axial spondyloarthritis in adults with chronic back pain in China.

  Recruiting Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07724847

• Canakinumab use in Schnitzler’s syndrome in real-world patients

  This study tests how well and how safely canakinumab works for people diagnosed with Schnitzler’s syndrome who are taking it in routine clinical care.

  Recruiting at 5 sites Novartis · Kobe, Hyōgo and 4 other locations · NCT07598422

• GenSci048 vs placebo in active non-infectious uveitis

  This study tests whether GenSci048 can help people with active non-infectious uveitis compared with placebo.

  Recruiting Phase 2 Changchun GeneScience Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT07547995

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.